



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 3 April 2019 (#10)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

Important Notices & News

NIH career development opportunities for global health researchers.

- [NIH Office of Intramural Training and Education Visiting Fellows](#) - NIH Office of Intramural Training and Education Visiting Fellows - Postdoctoral training in the NIH Intramural Research Program (IRP) for citizens of countries other than the U.S.
- [National Cancer Institute \(NCI\) Center for Global Health Short-term Scientists Exchange Program \(STSEP\)](#) - Highly-qualified cancer scientists, researchers and experts work alongside scientists at a host NCI intramural laboratory, division, office or center.
- [National Institute on Drug Abuse \(NIDA\) International Fellowships](#) - Scientists at various stages of their career path come to the U.S. and train with NIDA-supported researchers.
- [NIH Office of Clinical Research Sabbatical in Clinical Research Management](#) - Experienced clinical research investigators and mid-career managers of clinical research programs are connected with NIH experts for a 4- to 8-week independent study.

NIH is demonstrating accountability and transparency

- **NIH is demonstrating accountability and transparency** through its efforts to [address sexual harassment in science](#): "We want to send a clear message to the institutions we fund and researchers who lead the research that sexual harassment is unacceptable." For additional information please visit the NIH [Anti-Sexual Harassment: for NIH Awardee Organizations and Those Who Work There](#) webpage.
- **When conducting clinical trials**, NIH funding recipients are [required to register their study](#) at ClinicalTrials.gov. To make registration easier, a new feature in the eRA Human Subjects System (HSS) allows applicants and recipients to export study record entries as an XML file, and upload fields that are captured in both systems directly into ClinicalTrials.gov's Protocol Registration and Results System (PRS). For step-by-step instructions and more information, see [How to Upload Studies to ClinicalTrials.gov](#) and the [HSS: How to Export Study Record Data](#) video.

NIH Early Stage Investigator (ESI) Policy

- **Do you have questions on the NIH Early Stage Investigator (ESI) Policy?** Check out the following highlighted [frequently asked questions \(FAQ\)](#) for information on how NIH defines and reviews ESI applications to promote the growth and stability of the biomedical research workforce.

PEPFAR

- NIH requires that foreign nongovernmental organizations funded under the President's Emergency Plan for AIDS Relief agree to the terms and conditions of the [Protecting Life in Global Health Assistance policy](#).

Renewal applications

- **Is your Grant Coming to an End?** [Avoid and Survive a Funding Gap. Apply for the Renewal Early](#). As you contemplate a renewal application, remember whether you're on your first grant or you have had decades of support, renewal is never guaranteed. For the past several years, only about one-third of renewal applications have succeeded and most of those failed on the first attempt. Consider also other options if NIH is your sole source of funding; though few organizations can match NIH in scope, duration, and amount of support, avenues like foundations and endowments are great ways to get funding to generate preliminary data for new projects. **Be mindful of effort commitments.** Remember as you balance multiple avenues for funding that your effort level cannot exceed 100 percent. However, you can apply for multiple awards with total effort levels that exceed 100 percent. NIH allow this because you are not likely to get every grant you apply for. If multiple applications are funded, NIH will work with you during award negotiation to adjust your effort to be no more than 100 percent.
- **Remember when planning the budget for your next renewal application that** [NIAID caps R01 renewal budgets at 20 percent over the direct costs](#) of the last noncompeting award, excluding several categories of costs.

Other

- NIH Releases Protocol Template for Behavioral and Social Sciences Research Involving Humans ([NOT-OD-19-092](#))
- Broad Agency Announcement (BAA): Development of Vaccines for the Treatment of Opioid Use Disorder BAA-DAIT-75N93019R00009 ([NOT-AI-19-052](#))

1. BLOODSAFE: Research to enhance availability of safe blood for patients with severe anemia and hemorrhagic conditions in low or lower-middle income countries (LLMICs) in Sub-Saharan Africa (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-HL-20-009\)](#)

Type: UG3/UH3

Application Due Date: May 20, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement will support projects to enhance the availability and delivery of safe blood to be used for transfusion in patients from low or lower-middle income countries (LLMICs) in Sub-Saharan Africa (SSA). For example, ensuring that children with malaria or sickle cell disease and pregnant women who suffer from obstetric hemorrhage have access to safe transfusion therapies is of high programmatic interest. BLOODSAFE will support projects that develop and test feasible, effective and sustainable strategies to increase the number of safe blood donors, to improve quality and safety of blood supplies, and to enhance blood delivery to patients in need, especially in remote settings.

Budget: NHLBI intends to commit total costs of up to \$1,300,000 in fiscal year FY2020 and in FY2021, \$ 1,900,000 per year in FY2022 through FY2024, and \$1,300,000 in FY 2025 to fund up to 3 awards. Application budgets are limited to direct costs of up to \$415,000 in FY2020 and in FY2021 (UG3 Phase), \$580,000 per year in FY2022 through FY2024 (UH3 Phase), and \$415,000 in FY2025 (UH3 Phase). Applicants may request up to 2 years for the UG3 phase and up to 4 years for the UH3 phase. The maximum project period is six years.

2. BLOODSAFE: Research to enhance availability of safe blood for patients with severe anemia and hemorrhagic conditions in low or lower-middle income countries (LLMICs) in Sub-Saharan Africa - Data Coordinating Center (DCC) (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-HL-20-010\)](#)

Type: U01

Application Due Date: May 20, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement will support a Data Coordinating Center (DCC) to conduct the activities of the BLOODSAFE program, to enhance the availability and delivery of safe blood for transfusion for patients in low or lower-middle income countries in Sub-Saharan Africa. Refer to RFA-HL-20-009 for detailed information on the BLOODSAFE program FOA. The primary responsibilities of the DCC are to coordinate the activities of the research consortium, assist with program oversight by NHLBI, provide expertise in study design and management as well as data management and analysis, develop common measures and outcomes, ensure data quality, and facilitate collaboration and mutual learning among all research teams

Budget: NHLBI intends to fund a single award of total costs up to \$1,300,000 in fiscal year (FY) 2020. Application budgets are limited to direct costs of \$850,000 in FY2020, \$740,000 in FY2021, \$585,000 in FY2022 through FY2024, and \$810,000 in FY2025. The maximum project period is six years.

3. Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-19-220\)](#)

Type: U01

Application Due Date: August 14, 2019; February 19, 2020; August 19, 2020; February 17, 2021; August 18, 2021; February 16, 2022

Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. Through the support of trial readiness studies, NINDS and NCATS expect to enhance the quality and increase the likelihood of success of clinical trials in these rare diseases.

Budget: Application budgets are limited to \$650,000 in direct costs in any project year. The maximum project period is 5 years.

4. Research Project Grants in Pediatric Rehabilitation (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-HD-20-005\)](#)

Type: R01

Application Due Date: June 27, 2019 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: In this funding opportunity announcement (FOA), the National Center for Medical Rehabilitation Research within NICHD invites applications for research project grants addressing the rehabilitation needs of children with chronic, physical disabilities.

Budget: NICHD intends to commit a total of \$2 million in FY 2019 to fund up to 4 awards. Application budgets are limited to \$499,999 direct costs per year and need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

5. Advancing Biomarker Discovery and Novel Point-of-Care Diagnostics for Active TB Disease Detection in HIV-1 Infected and Exposed Children (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-AI-19-036\)](#)

Type: R01

Application Due Date: July 30, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The objective of this FOA is to advance non-sputum-based tuberculosis (TB) diagnostics for use in HIV-1 infected and HIV-1 exposed uninfected children (HEU) for improved, simplified, rapid and decentralized diagnosis of TB disease. This opportunity will support discovery and validation of novel biomarkers useful for TB diagnosis or the development/optimization and early validation of novel TB diagnostic technologies.

Budget: NIAID intends to commit \$3.08 million in FY 2020 to fund 4 to 5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

6. Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-CA-19-038\)](#)

Type: R21

Application Due Date: June 11, 2019; November 20, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Potential applicants who are interested in downstream technology development, from prototyping to hardening and adaptation, should consult the other companion FOAs listed above.

Budget: NCI intends to commit \$1,240,000 in FY 2020 to fund 6 awards. Direct costs are limited to \$275,000 over a two year period. No more than \$200,000 may be requested in any single year. The maximum project period is two years.

7. NEI Clinical Research Study Planning Grant Program (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-19-231\)](#)

Type: R34

Application Due Date: [Standard dates](#) & [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a well-documented Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This FOA is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed MOP. The NEI Clinical Study Planning Grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.

Budget: The NEI permits direct costs up to \$150,000 per year plus applicable F&A for consortia. The maximum period is two years.

8. Early-Stage Development of Informatics Technologies for Cancer Research and Management (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-CA-19-039\)](#)

Type: U01

Application Due Date: June 11, 2019; November 20, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

Budget: NCI intends to commit \$2,250,000 in FY 2020 to fund 5-6 awards. Budgets are limited to \$300,000 Direct Costs (excluding consortium F&A) per year. The maximum project period is three years.

9. Advanced Development of Informatics Technologies for Cancer Research and Management (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-CA-19-040\)](#)

Type: U24

Application Due Date: June 11, 2019; November 20, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the companion FOAs listed above.

Budget: NCI intends to commit \$3,600,000 in FY 2020 to fund 4 awards. Budgets are limited to \$600,000 Direct Costs (excluding consortium F&A) per year. The maximum project period is five years.

10. Sustained Support for Informatics Technologies for Cancer Research and Management (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-CA-19-041\)](#)

Type: U24

Application Due Date: June 11, 2019; November 20, 2019 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefitted and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.

Budget: NCI intends to commit \$2,250,000 in FY 2020 to fund 2 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)